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Abstract
Colorectal cancer remains one of the major causes of 
cancer death worldwide. During the past years, the 
development of new effective treatment options has led 
to a considerable improvement in the outcome of this 
disease. The advent of agents such as capecitabine, 
irinotecan, oxaliplatin, cetuximab and bevacizumab 
has translated into median survival times in the range 
of 2 years. Intense efforts have focused on identifying 
novel agents targeting specifi c growth factor receptors, 
critical signal transduction pathways or mediators of 
angiogenesis. In addition, several clinical trials have 
suggested that some of these molecularly targeted drugs 
can be safely and effectively used in combination with 
conventional chemotherapy. In this article we review 
various treatment options combining cytotoxic and 
targeted therapies currently available for patients with 
metastatic colorectal cancer. 
© 2007 WJG. All rights reserved.
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INTRODUCTION
Chemotherapy remains the cornerstone of  treatment 
of  metastatic colorectal cancer (mCRC) and, with 
the exception of  a minority of  patients (pts) who are 
candidates for salvage surgery, the goal of  chemotherapy 
is palliation. Remarkable and clinically relevant advances 
have been made in the last 5 years in the treatment 
of  this disease, essentially owing to the introduction 
of  combination chemotherapy regimens containing 
oxaliplatin and irinotecan (CPT-11)[1]. The addition of  
either drug to 5-fluorouracil/leucovorin (5-FU/LV) 
proved to significantly increase overall response rates 
and survival times. Indeed, median overall survival is 
highly correlated with the percentage of  patients who 
receive the three cytotoxic agents in the course of  their 
disease. Results from a Phase Ⅲ study by Falcone et al[2] 
suggested that the up-front use of  a triplet combination of  
irinotecan, oxaliplatin and 5-FU/LV signifi cantly improved 
the outcome in terms of  response rate (RR) and survival 
times compared to a standard doublet of  irinotecan and 
5-FU/LV.
Interestingly, with the more recent incorporation 
of  bevacizumab and cetuximab into the treatment 
armamentarium, the median overall survival (OS) has 
doubled from 12 mo to approximately 2 years in Phase 
Ⅲ trials. In fact, most recent trials that attempt to expose 
patients to all five drug classes (f luoropyrimidines, 
irinotecan, oxaliplatin, bevacizumab and anti-EGFR 
antibody) target an OS well over 2 years. In this review 
we will summarize some of  the available therapeutic 
repertoire based on targeted therapies in combination with 
chemotherapy for patients with mCRC.
COMBINING CHEMOTHERAPY AND EGFR-
TARGETED THERAPIES
The epidermal g rowth factor receptor (EGFR), a 
transmembrane tyrosine kinase, is one of  four members of  
the HER receptor family. This receptor is overexpressed in 
a number of  solid tumors of  ectodermal origin, including 
colon adenocarcinoma[3]. EGFR over expression has been 
correlated with disease progression, poor prognosis and 
reduced sensitivity to chemotherapy[4]. Therefore, several 
strategies have been developed to target EGFR, including 
small molecule tyrosine kinase inhibitors and monoclonal 
antibodies[5]. 
Cetuximab-based combination therapy
Cetuximab is the most advanced monoclonal antibody 
against EGFR in clinical development. Since preclinical 
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and early clinical studies suggested that Cetuximab might 
revert irinotecan resistance in CRC both in vitro and 
in vivo, a phase Ⅱ trial of  cetuximab with irinotecan was 
performed in patients with EGFR positive colorectal 
cancer that was refractory to both 5-fluorouracil (5-FU) 
and Irinotecan. Among the 120 patients treated with this 
regimen, overall response rate was 22.5%[6].
To confi rm these clinical fi ndings, 329 EGFR-positive, 
irinotecan-refractory mCRC patients were randomized in 
a 2:1 ratio to receive cetuximab plus irinotecan (arm A; 
n = 218) or cetuximab alone (arm B; n = 111) with the 
option to switch to the combination of  cetuximab with 
irinotecan after failure of  cetuximab as a single agent. Both 
the response rate (22.9% vs 10.8%, P = 0.007) and the 
median time to progression (4.1 vs 1.5, P < 0.001) favored 
the combination arm. Although no survival benefit was 
observed for arm A, cetuxibab was demonstrated to 
have clinically signifi cant activity when given alone or in 
combination with irinotecan and consequently received 
FDA approval[7].
More recently, MABEL trial [8] investigated the 
combination of  cetuximab and CPT-11 at a dose and 
schedule as pre-study in an uncontrolled, multicenter study 
including 1123 mCRC pts with detectable EGFR. 64% 
of  the patients had received ≥ 2 lines of  chemotherapy. 
76% had also been pretreated with cetuximab. The 
estimated median survival was 9.2 mo at as expense of  an 
acceptable toxicity profile, including grade 3-4 diarrhea 
(20%) acne-like rash (19%), neutropenia (9%) and asthenia 
(8%). MABEL clearly confirmed in a wider setting the 
effi cacy and safety or C225 plus CPT-11 seen in previous 
studies. Similarly, EPIC trial is a randomized phase Ⅲ 
trial comparing cetuximab plus irinotecan to irinotecan 
as second line therapy in patients with EGFR-expressing 
mCRC who have failed fi rst line oxaliplatin in combination 
with a fl uorpyrimidine. Accrual is currently ongoing[9].
Cetuximab-based combinations as salvage therapy: 
Several trials have addressed the potential of  cetuximab-
based combinations in heavily pretreated patients. 
Vincenzi et al[10] evaluated the effi cacy of  cetuximab plus 
oxaliplatin in patients previously failed on an oxaliplatin-
based regimen in first line, irinotecan-based regimen in 
second line, and cetuximab plus irinotecan in third line. No 
objective clinical response was identifi ed after the interim 
analysis planned according to the two-staged Simon 
accrual design. The same group[11] evaluated the activity of  
cetuximab and weekly irinotecan (90 mg/m2) in patients 
refractory to one oxaliplatin-based chemotherapy regimen 
(Capecitabine + Oxaliplatin or FOLFOX Ⅳ regimen, as 
first line) and one Irinotecan-based based-chemotherapy 
(FOLFIRI regimen, as second-line chemotherapy) for 
at least 2 mo. Overall response rate was 25.4% (95% CI: 
21.7%-39.6%); 38.2% (95 CI: 18.6%-39.8%) of  patients 
showed a disease stability as the best response. The median 
time to progression was 4.7 mo (95% CI: 2.5-7.1 mo) and 
the median survival time was 9.8 mo (95% CI: 3.9-10.1 
mo). The most common G3-4 noncutaneous side toxicities 
were diarrhoea (16.4%), fatigue (12.7%), stomatitis 
(7.3%) and skin toxicity (32.6%). A statistically signifi cant 
(P = 0.006) association between the cutaneous toxicity 
and both tumour response and time to progression 
was observed. The authors also identified a borderline 
signifi cant difference in terms of  overall survival.
The combination of  Cetuximab plus FOLFIRI has 
been prospectively evaluated in 41 EGFR expressing 
mCRC pts refractory to prior FOLFIRI for metastatic 
disease[12]. Most of  the patients were treated in third line. 
A 20% overall response rate was recorded, with a median 
PFS of  4.3 mo and a median overall survival of  5 mo.
Cetuximab-based combinations in front-line therapy: 
Cetuximab established activity in the salvage setting 
prompted its incorporation to first-line combination 
therapy. Available preliminary data from Phase Ⅱ trials 
combining cetuximab with either irinotecan or oxaliplatin-
based chemotherapy have shown very encouraging activity. 
CALGB 80203[13] randomized untreated mCRC patients to 
FOLFOX or FOLFIRI with or without C225 independent 
of  EGFR status. ORR was similar in the FOLFIRI or 
FOLFOX arms, while C225 containing arms had a higher 
ORR (49% vs 33%, P = 0.014) when compared to non 
cetuximab containing arms. No signifi cant differences in 
grade 3 diarrhea or any grade 4 toxicity were seen with the 
addition of  C225. Preliminary results of  the combination 
of  C225, capecitabine (800 g/m2 bid po on d 1 to 14) and 
Irinotecan (200 g/m2 i.v on d 1) vs C225 combined with 
capecitabine (1000 mg/m2 bid in d 1-14) and oxaliplatin 
(130 g/m2 on d 1) reported an overall response rate of  
41% (95%; 22% to 61%) and 71% (95%; 48% to 89%) 
respectively, with both arms showing a manageable toxicity 
profi le[14]. 
Promising results have also been reported[15] combining 
cetuximab with (AIO) infusional 5-FU/FA plus irinotecan 
regimen  in EGFR-expressing mCRC.Grade 3 or 4 
toxicities were acne-like rash (38%), diarrhea (29%), 
cardiovascular events (20%) and nausea/vomiting (5%). 
Objective responses were observed in 67% of  the patients. 
The median time to progression was 9.9 mo and the 
median survival time was 33 mo.
The combinat ion of  cetuximab with modif ied 
FOLFOX 6 in 83 chemo-naive mCRC pts with positive or 
undetectable EGFR expression show a preliminary ORR 
of  53%[16]. Main grade 3-4 toxicities included neutropenia 
(38%), diarrhea (10%), rash (10%) and neurotoxicity (7%). 
The combination of  FOLFOX-4 plus C225[17] has also 
been evaluated in 47 EGFR-expressing mCRC, with a 
reported ORR of  68%. Grade 3-4 adverse events included 
acne-like rash (18%) diarrhea (7%), nausea and vomiting 
(4%) and anemia (4%). 
Preliminary results of  the OPUS trial[18], a randomized 
phase Ⅱ study in the first line treatment of  mCRC, 
confirmed the superiority of  FOLFOX plus cetuximab 
vs FOLFOX in terms of  overall response rate (45.6% vs 
36.8%). 
These small tr ia ls suppor ted the conduct of  a 
multicenter Phase Ⅲ clinical trial that compared FOLFIRI 
plus Cetuximab with FOLFIRI alone in 1217 EGFR-
expressing chemotherapy-naive patients. Cetuximab 
plus FOLFIRI significantly increased response rate and 
progression-free survival, reducing the relative risk of  
progression by approximately 15%[19].
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Panitumumab-based combination therapy
Panitumumab is a fully human IgG2 monoclonal antibody 
directed against the epidermal growth factor receptor. 
Its use in combination with IFL and FOLFIRI in first 
line treatment of  metastatic CRC has been evaluated in a 
multicenter, single arm, phase 2 trial[20]. Panitumumab was 
given at a weekly dose of  2.5 mg/kg i.v. over 60-90 min 
followed by chemotherapy. The combination with IFL 
was considered too toxic, with grade 3-4 diarrhea in 
47% of  the patients. The FOLFIRI plus panitumumab 
combination was associated with a more manageable side 
effect profi le with grade 3-4 diarrhea in 25% of  the pts and 
grade 3-4 hypomagnesemia in 8%. Skin and nail toxicities 
occurred in at least 20% of  patients but were rarely severe 
(grade 3 in 2 out of  24 pts). The objective response rate 
with FOLFIRI plus panitumumab was 66%, with a disease 
control rate of  79%. Median progression free survival 
was 10.9 mo. Further investigation of  FOLFIRI with an 
every two weeks schedule of  panitumumab is ongoing in 
randomized phase 3 trials.
Cetuximab-induced papulopustular skin rash is thought 
to be mechanism- and dose-related, and may be a surrogate 
indicator of  an adequate degree of  receptor saturation 
by cetuximab. The possibility of  increasing Cetuximab 
effi cacy by inducing skin rash has been recently confi rmed. 
Cetuximab dose escalation up to 500 mg/m2 improves 
response rate in patients with absent or slight skin reaction 
on standard dose treatment[21].
Future directions
Large studies validating molecular predictive markers are 
needed in order to identify the subset of  patients more 
likely to respond to EGFR-targeted therapies. Candidate 
markers include total and phosphorylated EGFR, total and 
phosphorylated forms of  AKT, mitogen-activated protein 
kinase (MAPK), mitogen-activated protein/ERK (MEK), 
ERK, signal transducers and activators of  transcription 
(STAT), PTEN and mTOR[22] Although EGFR gene copy 
number has also been proposed[23], EGFR amplifi cation, 
measured by FISH is a rare event (4%) in colorectal 
cancer[24]. Other potential predictive markers are k-ras[25] 
cyclin D1 A870G polymorphisms[26], HER-2 expression[27] 
or higher gene expression levels of  VEGF[28]. More 
recently, a combination of  various predictive biomarkers 
has retrospectively been able to identify subsets of  patients 
more likely to benefit from cetuximab therapy[29]. In 
addition, several polymorphisms in genes involved in the 
EGFR and angiogenesis pathway have been associated 
with clinical outcome[30]. Prospective studies are clearly 
needed to confi rm these preliminary fi ndings.
EGFR tyrosine kinase inhibitor (TKI)-based combination
therapy 
Gefitinib: Gefitinib (ZD1839) selectively inhibits the 
EGFR tyrosine kinase and has approximately 100-fold 
greater potency against EGFR compared with other 
tyrosine or serine/threonine kinases. Unlike cetuximab, 
gefitinib does not induce EGFR internalization or 
degradation in CRC cells, nor does it reduce EGF 
binding sites or EGFR protein content. Both in vitro 
and in vivo studies indicated that gefitinib monotherapy 
had antitumour activity in some CRC cell l ines[31]. 
However, phaseⅠ/Ⅱ clinical studies in patients with 
mCRC indicated that gefi tinib had negligible activity[32,33]. 
Preclinical suggestions of  a supra-additive, growth-
inhibitory effect of  gefitinib and a wide variety of  
cytotoxic drugs with different mechanism(s) of  action[34] 
prompted several trials of  gefitinib in combination with 
chemotherapy in mCRC patients.
Gefi tinib plus fl uoropyrimidines: In preclinical models 
a strong synergistic interaction between gefitinib and 
5'-deoxy-fluorouridine (5'-DFUR) was demonstrated 
when ZD1839 was applied before or concurrently 
with 5'-DFUR[35]. Subsequently, the combination of  
intermittent gefitinib (250-500 mg/d on d 1-14) plus 
5-FU/LV administered as a bolus in a dose-reduced Mayo 
Clinic regimen (370/20 mg/m2) on d 8-12 with 5-FU 
and leucovorin as fi rst-line therapy in mCRC was tested, 
with no evidence of  cumulative toxicity or major drug-
drug pharmacokinetic interactions[36]. In the second part 
of  the study, gefitinib was administered continuously at 
500 mg/d, and 5-FU/LV was added to the schedule on d 
8-12 and 36-40. Overall response rate was 23%, with the 
most common toxicities being rash and diarrhea. 
Preliminary results from a small phaseⅠ/Ⅱ trial 
combining gefitinib 250-mg daily  with capecitabine 
1000-1250 mg  twice daily after failure of  first-line 
therapy[37] also suggest some evidence of  activity . 
Gefitinib plus irinotecan-based therapy: A dose-
fi nding trial of  irinotecan plus gefi tinib in mCRC patients 
pretreated with fluoropyrimidine-based chemotherapy 
defined irinotecan given at a dose of  225 mg/m2 every 
3 wk plus gefi tinib at a dose of   250 mg/d as the maximun 
tolerated dose (MTD) of  this regimen[38]. Dose-limiting 
toxicities (DLTs), such as neutropenia and diarrhea, 
occurred at unexpectedly low doses of  irinotecan. Disease 
stabilization was achieved in 21% of  the patients. 
The combination of  gefitinib plus FOLFIRI in both 
chemotherapy-naive mCRC patients[39] and as salvage 
therapy[40] was considered too toxic despite reduced weekly 
doses of  5-FU, LV, and irinotecan.
Gefitinib plus oxaliplatin-based therapy: Gefitinib 
plus FOLFOX has been tested in both the fi rst line and 
the salvage setting. Kuo et al[41] reported data on a phase 
Ⅱ study of  one cycle of  FOLFOX-4, and then additional 
cycles of  FOLFOX-4 with 500 mg/d of  gefitinib in 27 
patients with documented progressive colorectal cancer 
after at least one chemotherapeutic regimen (usually 
irinotecan based). 33% of  the patients achieved objective 
responses, whereas 48% had stable disease for a prolonged 
period. Response rates did not differ depending on 
number of  prior regimens. Median event-free survival 
was 5.4 mo, and overall survival was 12 mo. Another 
feasibility study assessed the combination of  gefitinib 
(250 mg/d) plus capecitabine (2000 mg/m2 per day, d 1-15) 
plus oxaliplatin (120 mg/m2 every 3 wk for six courses) 
as first-line treatment in patients with mCRC[42]. The 
most common grade 3 adverse events were diarrhea and 
neutropenia. A clinical benefi t rate of  58% has been noted. 
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Overall, toxicity rates with the addition of  gefi tinib to an 
oxaliplatin-fluoropyrimidine combination are markedly 
more favorable than with the irinotecan-based regimens, 
although higher incidences of  grade Ⅲ or Ⅳ diarrhea, 
nausea, and vomiting than with FOLFOX alone are noted. 
Further studies of  TKI-based therapy for CRC are planned 
or recruiting.
Erlotinib: Erlotinib, an orally reversible TKI reduces 
intratumoral EGFR autophosphorylation[43] with no effect 
on EGFR expression or surface receptor density. Evidence 
of  single agent erlotinib activity in mCRC patients derived 
from disease-specifi c phase Ⅱ studies[44] led to the design 
of  several trials in combination with chemotherapy.
Tarceva plus fluoropyrimidines: Additive activity of  
capecitabine and erlotinib in tumor models[45] supported a 
phase 2 trial evaluating the combination of  erlotinib 150 
mg daily with capecitabine 1000 mg/m2 bid. for 14 d every 
3 wk in chemotherapy-naive mCRC patients. Grade 3 
diarrhea (30%) grade 3 renal insuffi ciency (10%) and grade 
3 hiperbilirrubinemia (10%) were the most troublesome 
toxicities. Regarding effi cacy, no complete responses were 
achieved whereas disease control rate was 34%[46]. 
Tarceva plus oxaliplatin: Meyerhardt et al[47] reported on 
the results of  a triplet regimen of  erlotinib, 100 mg/d, 
capecitabine, 1650 mg/m2 per day (d 1-14), and oxaliplatin, 
130 mg/m2 every 3 wk in 32 patients mostly pretreated 
with an irinotecan-containing regimen. By intent-to-treat 
analysis, 25% of  the patients experienced a partial response 
and 44% had stable disease for at least 12 wk. 29% of  the 
patients discontinued study therapy due to toxicity.
Other TKIs-based combinations
EKB-569, an irreversible dual inhibitor of  the EGFR and 
HER-2 tyrosine kinases, inhibits the growth of  tumor cells 
that overexpress EGFR or HER-2 in vitro and in vivo[48]. 
Dose-limiting toxicities with EKB-569 plus FOLFIRI in 
47 chemotherapy-naive mCRC patients[49] were grade 3 
diarrhea and grade 3 fatigue. The MTD was selected as 
25 mg EKB-569. The response rate was 38% and the 
clinical benefi t rate was 85%. EKB-569 treatment resulted 
in complete inhibition of  pEGFR and signifi cant inhibition 
of  pMAPK in both skin samples (11 patients) and tumor 
samples (three patients) with no change in pAkt activity. 
In a dose-escalation study[50] with FOLFOX-4 plus 
EKB-569, 25-75 mg/d, starting from d 3, DLTs were 
observed with EKB-569 at a dose of  35 mg/d (grade Ⅲ 
diarrhea and febrile neutropenia), leaving an MTD of  25 
mg/d. The most common grade Ⅲ or Ⅳ adverse events 
were neutropenia (32%; 9 of  29 patients) and diarrhea 
(8%; 2 of  29 patients).
COMBINING CHEMOTHERAPY AND VEGF-
TARGETED THERAPIES
Bevacizumab
Clinical development of  Bevacizumab (BV) has rapidly 
progressed to Phase Ⅲ trials after a preliminary randomized 
Phase Ⅱ trial in which 104 previously untreated mCRC 
patients were randomized to two doses of  BV (5 and 10 
mg/kg) in addition to bolus 5-FU/LV (high dose, Rosewell-
Park regimen) or to 5-FU/LV alone[51]. The combination 
of  5-FU/LV with low-dose BV (5 mg/kg every 2 wk) 
demonstrated superiority compared with the control 
monotherapy arm and to the BV-containing arm at a higher 
dose. These results provided the rationale for the key front-
line Phase Ⅲ study by Hurwitz et al[52] which demonstrated 
superiority of  IFL plus BV over IFL plus placebo in terms 
of  RR (45% vs 35%), PFS(10.6 mo vs 6.2 mo) and OS(20.3 
mo vs 15.6 mo). A subanalysis of  this trial has recently 
stablished the benefi t of  Bevacizumab in mCCR patients 
with poor conditions[53].
The second trial (E3200) was a second-line Phase 
Ⅲ study, designed for patients who already failed an 
irinotecan-containing therapy and did not receive BV in 
first-line treatment[54]. Initially, the study included three 
randomization arms: FOLFOX4 plus BV 10 mg/kg, 
FOLFOX4 alone or BV 10 mg/kg alone. The BV single-
agent arm was closed ahead of  time since it was clearly 
inferior to both other arms (RR 3% and PFS 2.7 mo). 
The results again largely favored the BV-containing arm, 
especially in terms of  RR (21.8% vs 9.2%, P < 0.0001) 
and PFS (7.2 mo vs 4.8 mo, P < 0.0001). The primary 
end point of  the study was reached, since a statistically 
signifi cant increase in median survival was obtained in the 
experimental arm (12.5 mo vs 10.7 mo, P < 0.0024).
Finally, updated results of  N016966, a randomized 
phase Ⅲ trial evaluating the addition of  bevacizumab 
to oxaliplatin-based first line chemotherapy have been 
reported. Bevacizumab-containing arms demonstrated a 
significant benefit in terms of  progression-free survival, 
although overall response rate did not signifi cantly differ[55]. 
More recently, several phase Ⅱ trials have addressed 
the feasibility and activity of  bevacizumab when combined 
with various cytotoxic regimens. The First BEATrial[56] 
enrolled 1927 chemotherapy-naïve patients treated with 
a combination of  bevacizumab and several first-line 
chemotherapies, including FOLFOX, FOLFIRI and 
XELOX. Median PFS was 10.4 mo. Combinations of  
XELOX or XELIRI plus bevacizumab have yielded tumor 
control rates in the range of  80% as front-line therapy for 
mCRC[57].
In contrast to its efficacy when used in combination 
with first- and second-line chemotherapy, activity 
of  bevacizumab in chemoresistant disease has been 
dissapointing. Chen et al developed a treatment referral 
center (TRC) protocol (TRC-0301) for patients with 
mCRC in the third-line setting with the aim of  evaluating 
the safety and activity of  BV plus FU/LV in patients 
progressed after treatment with both irinotecan-based and 
oxaliplatin-based chemotherapy regimens[58]. Independent 
review confirmed one PR (1%; 95% CI, 0% to 5.5%).  
Median PFS in this cohort was 3.5 mo (95% CI, 2.1 mo 
to 4.7 mo) and median OS was 9.0 mo (95% CI, 7.2 mo 
to 10.2 mo). The authors conclude that BV, alone or in 
combination with an ineffective chemotherapy in the 
third-line setting, is likely to be of  minimal, if  any, clinical 
benefi t.
An important question that remains unresolved is 
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whether to continue bevacizumab with second-line therapy 
following failure of  a bevacizumab-containing first-line 
regimen. Although retrospective data from the BRiTE 
trial suggest that the use of  bevacizumab beyond first 
progression correlate with an improved survival, more 
mature data are required to draw any fi rm conclusion[59].
VEGF Tyrosine kinase inhibitors (TKI)-based combination 
therapy
Tyrosine kinase inhibitors of  vascular endothelial growth 
factor receptors (VEGFRs) are low molecular weight, 
ATP-mimetic proteins that bind to the ATP-binding 
catalytic site of  the tyrosine kinase domain of  VEGFRs, 
resulting in a blockade of  intracellular signaling. Several of  
these molecules have entered clinical evaluation.
Semaxanib: Semaxanib is a small, lipophilic, synthetic 
molecule that inhibits VEGFR-1, and -2 tyrosine 
kinases[60]. A promising response of  31.6% was observed 
with semaxanib at two different dose levels, 85 and 145 
mg/m2 twice weekly in combination with fluorouracil 
plus leucovorin as first-line therapy for 28 patients with 
mCRC[61]. However, a randomized, multicenter, phase Ⅲ 
trial failed to show any improvement in clinical outcome 
with semaxanib in combination with fluorouracil and 
leucovorin (Roswell Park regimen) versus fluorouracil 
and leucovorin alone as first-line therapy for 737 mCRC 
patients; moreover, worse toxicity in the semaxanib arm 
(in terms of  diarrhea, cardiovascular events, vomiting, 
dehydration, and sepsis) was observed[62].
Vatalanib: Valatanib is a synthetic, low molecular weight, 
orally bio-available agent that inhibits all known VEGFR 
tyrosine kinases, platelet-derived growth factor receptor 
beta (PDGFR-β) and c-Kit tyrosine kinase[63].
Vatalanib was evaluated in two phaseⅠ/Ⅱ studies 
as a single daily dose in combination with FOLFOX-4 
or FOLFIRI. In the first study, the pharmacokinetics 
and toxicity profiles of  both vatalanib and FOLFOX-4 
were unaffected by co-administration[64]. The reported 
response rate was 54%, with a median PFS of  11 mo and 
an estimated median OS time of  16.6 mo . In the second 
study[65], co-administration of  vatalanib at 1250 mg/d with 
FOLFIRI had minor effects on irinotecan exposure but 
lowered by 40% the AUC of  SN-38 in patients’ serum. 
The response rate was 41%, with a median PFS duration 
of  7.1 mo and a median OS time of  24.3 mo. Two large, 
randomized, double-blinded, placebo-controlled, phase 
Ⅲ trials compared the efficacy of  oral vatalanib in 
combination with FOLFOX-4 with FOLFOX-4 alone in 
patients with mCRC, and none of  them met the primary 
end points. In the CONFIRM-2 trial, the addition of  
PTK/ZK to FOLFOX-4 in previously treated mCRC did 
not meet the primary end points of  the study. OS was 12.1 
mo in the PTK/ZK arm and 11.8 mo in the placebo arm. 
The overall response rate was, respectively, 18.5 and 17.5%. 
PFS was significantly longer in the PSK/ZK arm (5.5 
mo vs 3.8, P = 0.026) As in confi rm 1 trial, patients with 
pretreatment high LDH showed a strong improvement 
in PFS[66]. Adverse events were similar to those of  the 
CONFIRM-1 trial. Thrombotic and embolic events of  all 
grades occurred in 6% of  the patients treated with PTK/
ZK vs 1% in the placebo arm. Trying to further analyze 
the relation between LDH levels and clinical outcome 
with PTK/ZK, Fixed paraffi n embedded tumor samples 
from 36 mCRC not included in the CONFIRM trials were 
analyzed and tumor gene expression correlated with serum 
levels of  LDH in the same group of  patients. Intratumoral 
levels of  LAMA, hipoxia inducible factor 1 (HIF-1), 
Glut-1 and VEGFA were signifi cantly correlated. Moreover, 
pat ients with high serum LDH showed increased 
intratumoral gene expression of  VEGFA, supporting the 
hypothesis of  serum LDH levels as a surrogate maker for 
activation of  the hypoxia inducible factor related genes in 
the tumor[66]. 
AZD2171: Preliminary data of  a phase I evaluation 
of  AZD2171, a highly potent and selective inhibitor 
of  VEGFR signaling, in combination with several 
chemotherapy regimens including FOLFOX-6 and 
CPT-11, has shown some evidence of  activity[67].
Vandetalib: Vandetalib, a once-daily oral inhibitor of  
VEGFR-dependent tumor angiogenesis, EGFR- and 
RET-dependent tumor proliferation, in combination 
with FOLFOX6[68] or FOLFIRI[69] has also shown 
some evidence of  activity in mCRC, with diarrhea and 
neutropenia being the most frequent grade 3 toxicities.
 
Future directions
So far, clinical, biochemical, and molecular markers have 
failed to discriminate which patients are more likely to 
benefi t from bevacizumab-containing regimens. An analysis 
of  predictive markers showed indeed that bevacizumab 
increased the activity of  irinotecan plus FU/LV regardless 
of  the level of  VEGF expression, thrombospondin 
expression, and microvessel density[70]. Mutations of  k-ras, 
b-raf, and p53 could not predict for a prolonged survival 
on bevacizumab plus irinotecan plus bolus FU/LV[71]. 
Recently, Shaye et al evaluated functionally significant 
polymorphisms of  genes involved in the angiogenesis 
pathway in mCRC patients who receive bevacizumab as 
part of  their front-line therapy. There were statistically 
signifi cant associations between genomic polymorphisms 
of  KDR, CXCR2, MMP7, leptin and both progression-
free survival and response rate. Hopefully, prospectively 
collected samples from patients enrolled onto cooperative 
group studies and the development of  selective micro 
arrays to defi ne the angiogenesis-related genes in individual 
tumors, and at different stages of  therapy and tumor 
progression may allow improved therapeutic effi cacy.
COMBINATION OF TARGETED THERAPIES
The assumption that most advanced solid tumors derive 
their growth advantage from more than a signaling 
pathway and the signifi cant level of  compensatory cross 
talk among receptors within a signaling network as well as 
with heterologous receptor systems has provided the basis 
of  a combined molecular targeting approach, in which 
more than one class of  inhibitor is applied simultaneously. 
A phase Ⅱ study with the combination of  FOLFOX, 
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bevacizumab (5 mg/kg) and erlotinib (150 mg/d) every 
two weeks in 31 chemotherapy naive mCRC patients 
has been recently conducted. Grade 3-4 adverse events 
included diarrhea (29%) neutropenia (29%) rash (18%), 
fatigue (14%) and neuropathy (11%) 78% of  the patients 
had at least one grade 3-4 toxicity. Remarkably, as much as 
42% of  the patients came off  for toxicity. Similar results 
have been reported in the DREAM-OPTIMOX3 study, 
with a 70% incidence of  grade 3-4 toxicity when adding 
erlotinib to a combination of  bevacizumab and XELOX[73].
A phase Ⅱ trial of  FOLFOX plus bevacizumab and 
cetuximab in 67 chemotherapy-naïve mCRC patients 
yielded a 55% response rate, with a median PFS of  9.6 
mo and 71% of  the patients progression-free for at least 8 
mo[74]. 
The combination of  FOLFOX or FOLFIRI with 
panitumumab and AMG706, an oral multikinase inhibitor 
targeting VEGF, PDGF and Kit receptors has been 
tested in 45 mCRC patients, with no apparent PK/PD 
interactions and an overall response rate in the range of  
50%[75].
Based on these results, combinations of  monoclonal 
antibodies are currently being actively tested in first-line 
therapy of  mCRC. The Cancer and Leukemia Group 
B (CALGB)/South West Oncology Group (SWOG) 
Intergroup 80405 Phase Ⅲ trial randomizes patients to 
either cetuximab or bevacizumab, or both antibodies in 
combination, with the oncologist’s choice of  FOLFOX 
or FOLFIRI. In addition, the Panitumumab Advanced 
Colorectal Cancer Evaluation (PACCE) trial is currently 
evaluat ing the eff icacy of  FOLFOX or FOLFIRI 
(depending on the investigator choice) plus BV, versus the 
same combination plus panitumumab.
OTHER TARGETED THERAPIES-BASED 
COMBINATIONS
Cell cycle inhibitors
Kortmansky et al[76] reported the results of  the combi-
nation of  5-FU and UCN-01, a selective inhibitor of  a 
number of  serine-threonine kinases, including calcium 
and phospholipid-dependent protein kinase C and cell 
cycle specific kinases, among 35 patients with advanced 
solid tumors, the majority of  them with a diagnosis of  
mCRC. No objective responses were observed, although 
eight patients had stable disease. Most of  the patients with 
stable disease had previously received and progressed on 
5-fl uorouracil. There was minimal toxicity attributed to the 
combination, although expected toxicities associated with 
UCN-01 were observed.
Apoptosis modifi ers
Bcl-2 plays a pivotal role in the regulation of  caspase 
activation and apoptosis. Its overexpression is found in 
30%-94% of  clinocopathological colorectal carcinoma 
specimens and confers a multidrug resistant phenotype 
in several cell lines. In support of  this data, antisense 
oligonucleotide therapy directed against bcl-2 was 
shown to significantly enhance the chemosensitivity in 
several cancer cell lines compared with controls in vitro. 
A recently published phaseⅠtrial assessed the feasibility 
and pharmacokinetic behaviour of  the combination 
of  oblimersen sodium, a phosphorothioate antisense 
oligonucleotide that hybridizes to the fi rst six codons of  
the bcl-2 open reading frame mRNA, with CPT-11 in 20 
pts with mCRC. Among them, 1 pt experienced a PR while 
10 additional patients had stable disease lasting 2.5-10 mo. 
The authors recommend oblimersen at 7 g/kg/d, d 1-8 
with CPT-11 280 mg/m2 on d 6 once every 3 wk was the 
RD for further development in phase Ⅱ trials[77].
Proteasome inhibitors
The proteasome inhibitor Bortezomib (PS-341), at a 
dose of  1.3 mg/m2 administered twice weekly every 21 d 
in pretreated patients with mCRC did not prove to have 
clinical activity[78].
The main nonhematologic toxicities were elevation 
of  alkaline phosphatase, constipation, fatigue, nausea, 
and sensor y neuropathy. A phamacokinet ic and 
phamacodynamic analysis of  topotecan plus PS-341 in 22 
patients with advanced solid malignancies found that, with 
the addition of  PS-341, peripheral blood mononuclear 
cells (PBMC) topoisomeraseⅠlevels got stabilised or 
increased. These findings suggest that PS-341 may 
overcome resistance to topoisomeraseⅠinhibitors, since in 
vitro exposure to campothecin results in down-regulation 
of  the target enzyme. Preliminary data of  the combination 
of  FOLFOX4 plus bortezomib in mCRC patients[79] show 
evidence of  clinical activity, with bortezomib at a dose of  
1 mg/m2 being the RD for phase Ⅱ trials.
COX inhibitors
Numerous clinical trials are ongoing to test the efficacy 
of  nonsteroidal anti-inflammatory COX-2 inhibitors in 
combination regimens for therapy of  advanced solid 
tumors[80]. Preliminary data on the combination of  
rofecoxib (50 mg/d) with weekly irinotecan and infusional 
fluorouracil demonstrated a good tolerability up to the 
irinotecan dose of  125 mg/m2/wk. The phase Ⅱ study 
showed a 36.7% objective response rate, a clinical benefi t 
of  76.7% and a median TTP and overall survival of  4 and 
9 mo, respectively. The combination was feasible and safe, 
with a reduced rate of  mucositis and diarrhea[81].
However, in the BICC-C trial[82], addition of  celecoxib 
to several Irinotecan/fluorpyrimidine combinations did 
not impact safety or effi cacy. Results of  larger studies seem 
warranted.
Histone deacetylase inhibitors
Histone acetylation by histone acetyltransferases is 
important for promoting the action of  several transcription 
factors. Acetylation facilitates binding of  transcription 
factors to specifi c target DNA sequences by destabilizing 
nucleosomes bound to the promoter region of  the target 
genes[83]. 
Vorinostat, a novel histone deacetylase inhibitor that 
potentiates 5-FU through a decrease in tymidilate synthase 
(TS) expression has been tested in combination with 
FOLFOX, in a phaseⅠstudy that enrolled mCRC patients 
who had failed prior FOLFOX, irinotecan and cetuximab 
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therapy. Tolerance was acceptable, and some evidence of  
both, clinical activity (SD in some patients) and biological 
activity (down regulation of  TS) are suggested[84].
mTOR inhibitors
Rapamycin displays potent antimicrobial and immuno-
suppressant effects as well as antitumor properties. 
Rapamycin’s antiproliferative actions are due to it’s ability 
to modulate key signal transduction pathways that link 
mitogenic stimuli to the synthesis of  proteins necessary for 
the cell cycle to progress from the G1 to S phase[85].
Rapamycin clinical development has been hampered 
due to the poor aqueous solubility and chemical stability 
of  the macrolide. CCI-779, a rapamycin ester derived from 
2, 2-bis (hydroxymethyl) propionic acid, is one analog that 
was selected for further development due to its promising 
pharmacological, toxicological and antitumor profi les[86]. 
A phaseⅠstudy of  escalating doses of  CCI-779 in 
combination with 5-FU/leucovorin in patients with 
advanced solid tumors, including mCRC reported 
preliminary evidence of  activity including 1 complete 
response in a patient with mCRC receiving the 15 mg/m2 
dose and several patients with stable disease of  a maximum 
duration of  12 mo. Further studies are required to determine 
appropriate regimens with this combination treatment[87]. 
CONCLUSION
In conclusion, the biological agents have clearly increased 
the therapeutic armamentarium of  patients with metastatic 
CRC and offer also prospects for an increased chance 
of  a longer survival. Eventually, the availability of  more 
predictive biological factors may allow oncologists to tailor 
individualized targeted combination therapy to a specifi c 
patient with a specifi c tumor. However, the cost of  novel 
therapies for mCRC is particularly high. Such a heavy 
economical burden may be counterbalanced either by a 
very signifi cant breakthrough in treatment effi cacy or by 
selection of  patients with a higher chance of  responding 
to a specifi c treatment. 
REFERENCES
1 Kelly H, Goldberg RM. Systemic therapy for metastatic 
colorectal cancer: current options, current evidence. J Clin 
Oncol 2005; 23: 4553-4560
2 Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara 
C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, 
Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto 
L, Orlandini C, Andreuccetti M, Masi G. Phase III trial of 
infusional fl uorouracil, leucovorin, oxaliplatin, and irinotecan 
(FOLFOXIRI) compared with infusional fluorouracil , 
leucovorin, and irinotecan (FOLFIRI) as first-line treatment 
for metastatic colorectal cancer: the Gruppo Oncologico Nord 
Ovest. J Clin Oncol 2007; 25: 1670-1676
3 Goldstein NS, Armin M. Epidermal growth factor receptor 
immunohistochemical reactivity in patients with American 
Joint Committee on Cancer Stage IV colon adenocarcinoma: 
implications for a standardized scoring system. Cancer 2001; 
92: 1331-1346
4 Nicholson RI , Gee JM, Harper ME. EGFR and cancer 
prognosis. Eur J Cancer 2001; 37 Suppl 4: S9-S15
5 Mendelsohn J. Blockade of receptors for growth factors: an 
anticancer therapy--the fourth annual Joseph H Burchenal 
American Association of Cancer Research Clinical Research 
Award Lecture. Clin Cancer Res 2000; 6: 747-753
6 Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, 
Needle M, LoBuglio A. Cetuximab (IMC-C225) plus irinotecan 
(CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) 
that expresses epidermal growth factor rector (EGFR). Proc Am 
Soc Clin Oncol 2001; 20: 7 (Abstract)
7 Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, 
Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, 
Van Cutsem E. Cetuximab monotherapy and cetuximab plus 
irinotecan in irinotecan-refractory metastatic colorectal cancer. 
N Engl J Med 2004; 351: 337-345
8 Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, 
Aranda Aguilar A, Aapro M, Van Den Berg N, Eggleton S, 
Siena S. MABEL. A large multinational study of cetuximab 
plus irinotecan in irinotecan resistant metastatic colorectal 
cancer. Proc Am Soc Clin Oncol 2006; 158s: 3549 (Abstract)
9 Abubakr Y, Eng C, Wong L, Pautret V, Scheithauer W, Maurel 
J, Kroening H, lutz M, Zubel A, Sobrero A. Cetuximab plus 
irinotecan for metastatic colorectal cancer: Safety analysis of 
800 patients in a randomized phase III trial. Proc Am Soc Clin 
Oncol 2006; 160s: 3556 (Abstract)
10 Vincenzi B , Santini D, Tonini G. Lack of response of 
cetuximab plus oxaliplatin in advanced colorectal cancer 
patients resistant to both oxaliplatin and cetuximab plus 
irinotecan. Ann Oncol 2006; 17: 527-528
11 Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel 
B, Trodella L, Tonini G. Cetuximab and irinotecan as third-line 
therapy in advanced colorectal cancer patients: a single centre 
phase II trial. Br J Cancer 2006; 94: 792-797
12 Smith DM, Legoux J, Brunet R, Adhoute X, Blanc J, Fonck 
M, Vendrely V, Becouarn Y. Cetuximab in combination with 
FOLFIRI in second and third line treatment of metastaic 
colorectal cancer: Safety and effi cacy analysis. Proc Am Soc Clin 
Oncol 2006; 160s: 3558 (Abstract)
13 Venook A, Niedzwiecki D, Hollis D, Sutherland S, Goldberg 
R, Alberts S, benson A, Wade J, Schilsky R, Mayer R. Phase 
III study of FOLFIRI or FOLFOX with or without cetuximab 
for patients with untreated metastatic adenocarcinoma of the 
colon or rectum: CALGB 80203 preliminary results. Proc Am 
Soc Clin Oncol 2006; 148s: 3509 (Abstract)
14 Heinemann V, Fischer Von Weikersthal L, Moosmann N, 
Vehling-Kaiser U, Stauch M, Oruzio D, Schulze M, Walther 
J, Weiss J, Dietzfelbinger H. Cetuximab + capecitabine + 
irinotecan versus cetuximab + capecitabine + oxaliplatin as 
fi rst line therapy for patients with metastatic colorectal cancer: 
Preliminary results of a randomized phase II trial of the AIO 
CRC Study Group. Proc Am Soc Clin Oncol 2006; 158s: 3550 
(Abstract)  
15 Folprecht G, Lutz MP, Schoffski P, Seufferlein T, Nolting 
A, Pollert P, Kohne CH. Cetuximab and irinotecan/5-
fl uorouracil/folinic acid is a safe combination for the fi rst-line 
treatment of patients with epidermal growth factor receptor 
expressing metastatic colorectal carcinoma. Ann Oncol 2006; 
17: 450-456
16 Dakhil S, Cosgriff T, Headley D, Boccia RV, Badarinath S. 
Cetuximab plus FOLFOX-6 as fi rst line therapy for metastatic 
colorectal cancer. (An International Oncology Network study, 
I-03-002.). Proc Am Soc Clin Oncol 2006; 160s: 3557 (Abstract)
17 Colucci G, Giuliani F, Mattioli R, Garufi  C, Mallamaci R, Pezella 
G, Lopz M, Maiello E. FOLFOX-4 plus cetuximab in untreated 
patients with advanced colorectal cancer. A phase II study of 
the Gruppo Oncologico dell'Italia Meridionale (prot GOIM 
2402. Proc Am Soc Clin Oncol 2006; 160s: 3559 (Abstract)
18 Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, 
Aparicio J, Zampino M, Donea S, Ludwig H, Zubel A, 
Koralewski P. Cetuximab plus FOLFOX versus FOLFOX4 in 
the fi rst line treatment of metastatic colorectal cancer: OPUS, a 
randomized phase II study. Proc Am Soc Clin Oncol 2007; 172s: 
4035 (Abstract)
19 Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin 
I, Maurel J, Rougier P, Cunningham D, Nippgen J, Kohne 
C. Randomized phase III study of FOLRIRI with or without 
Rodriguez J et al.  Targeted therapies-based combinations                                                                                  5873
www.wjgnet.com
Cetuximab in the first line treatment of patients with 
metastatic colorectal cancer: The CRYSTAL trial. Proc Am Soc 
Clin Oncol 2007; 164s: 4000 (Abstract)
20 Hecht J, Posey J, Tchekmedyian S, Hu E, Chan D, Malik I, 
Yang L, McDonald M, Berlin J. Panitumumab in combination 
wiyh 5-fl uorouracil, leucovorin, and irinotecan or FOLFIRI for 
fi rst line treatment of metastatic colorectal cancer. Proc Am Soc 
GI Symp 2006: 237 (Abstract)
21 Teipar S, Peeters M, Humblet Y, Gelderblom H, Vermorken 
J, Viret F, Glimelius F, Ciardiello F, Kisker O, Van Cutsem E. 
Phase I/II study of cetuximab dose escalation in patients with 
metastatic colorectal cancer with no or slight skin reactions 
on cetuximab standard dose treatment (EVEREST study).
Pharmacokinetic, Pharmacodynamic and efficacy data. Proc 
Am Soc Clin Oncol 2007; 172s: 4037 (Abstract)
22 Gravalos C, Sastre J, Aranda E, Massuti B, Vega-Villegas ME, 
Gomez A, Varella-Garcia M, Jimeno A, Diaz-Rubio E, Hidalgo 
M. Analysis of potential predictive factors of clinical benefi t in 
patients with matastatic colorectal cancer treated with single 
agent cetuximab as fi rst line treatment. Proc Am Soc Clin Oncol 
2007; 193s: 4120 (Abstract) 
23 Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-
Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli 
A. Gene copy number for epidermal growth factor receptor 
(EGFR) and clinical response to antiEGFR treatment in 
colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286
24 Garufi C, Mottolese M, Cianciulli A, Zeuli M, Buglioni S, 
Torsello A, Vanni B, Campanellaa C, Merola R, Terzoli E. 
Epidermal growth factor gene amplification is not frequent 
and cannot account for antitumor activity of cetuximab plus 
chemotherapy in advanced colorectal cancer patients. Proc Am 
Soc Clin Oncol 2006; 161s: 3561 (Abstract)
25 Di Fiore F, Le Pessot F, Lamy A, Charbonnier F, Sabourin 
J, Paillot B, Frebourg T, Michel P. K-ras mutation is highly 
predictive of cetuximab resistance in metastatic colorectal 
cancer. Proc Am Soc Clin Oncol 2007; 565s: 10502 (Abstract) 
26 Zhang W, Yun J, Press OA, Gordon M, Yang DY, Mallik N, 
Sherrod A , Iqbal S, Lenz HJ. Association of cyclin D1 (CCND1) 
gene A870G polymorphism and clinical outcome of EGFR-
positive metastatic colorectal cancer patients treated with 
epidermal growth factor receptor (EGFR) inhibitor cetuximab 
(C225). Proc Am Soc Clin Oncol 2004: 3518 (Abstract)
27 Emlet DR, Schwartz R, Brown KA, Pollice AA, Smith CA, 
Shackney SE. HER2 expression as a potential marker for 
response to therapy targeted to the EGFR. Br J Cancer 2006; 94: 
1144-1153
28 Vallbohmer D, Zhang W, Gordon M, Yang DY, Yun J, Press 
OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen 
S, Lenz HJ. Molecular determinants of cetuximab efficacy. J 
Clin Oncol 2005; 23: 3536-3544
29 Finocchiaro G, Capuzzo F, Janne PA, Bencardino K, Carnaghi 
C, Franklin WA, Roncalli M, Crino L, Santoro A, Varella-
Garcia M. EGFR, HER2 and Kras as predictive factors for 
cetuximab sensitivity in colorectal cancer. Proc Am Soc Clin 
Oncol 2007; 168s: 4021 (Abstract)
30 Nagashima F, Zhang W, Gordon M, Chang HM, Lurje G, 
Borucka E, Yang D, Rowinsky E, Lenz HJ. EGF, Cox-2 and 
EGF polymorphisms associated with progression-free survival 
of EGFR-expressing metastatic colorectal cancer patients 
treated with single agent cetuximab. Proc Am Soc Clin Oncol 
2007; 195s: 4129 (Abstract)
31 Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, 
Cuccato S, De Placido S, Bianco AR, Tortora G. Inhibition of 
growth factor production and angiogenesis in human cancer 
cells by ZD1839 (Iressa), a selective epidermal growth factor 
receptor tyrosine kinase inhibitor. Clin Cancer Res 2001; 7: 
1459-1465
32 Rothenberg ML, Lafleur B, Washington MK, Levy DE, 
Morgan-Meadows DE, Ramanathan RK, Berlin JD, Benson 
AIB, Coffey RJ. Changes in epidermal growth factor receptor 
signalling in serum and tumour biopsies obtained from 
patients with progressive metastatic colorectal cancer (MCRC) 
treated with gefitinib (ZD1839): An Eastern Cooperative 
Oncology Group Meeting. Proc Am Soc Clin Oncol 2004; 21: 
3000 (Abstract)
33 Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major 
PP, Miller WH Jr, Panasci L, Lorimer IA, Batist G, Matthews S, 
Douglas L, Seymour L. A phase II trial of ZD1839 (Iressa) 750 
mg per day, an oral epidermal growth factor receptor-tyrosine 
kinase inhibitor, in patients with metastatic colorectal cancer. 
Invest New Drugs 2005; 23: 165-170
34 Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, 
De Placido S, Bianco AR, Tortora G. Antitumor effect and 
potentiation of cytotoxic drugs activity in human cancer cells 
by ZD-1839 (Iressa), an epidermal growth factor receptor-
selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 
2053-2063
35 Magne N, Fischel JL, Dubreuil A, Formento P, Ciccolini J, 
Formento JL, Tiffon C, Renee N, Marchetti S, Etienne MC, 
Milano G. ZD1839 (Iressa) modifies the activity of key 
enzymes linked to fl uoropyrimidine activity: rational basis for 
a new combination therapy with capecitabine. Clin Cancer Res 
2003; 9: 4735-4742
36 Hammongd LA, Figueroa J, Schawrtzaberg L: Feasibility and 
pharmacokinetic (PK) trial of ZD1839 (Iressa), an epidermal 
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), 
in combination with 5-Fluororaucil (5-FU) and lecovorin (LV) 
in patients with advanced colorectal cancer. Proc Am Soc Clin 
Oncol 2001: 544 (Abstract)
37 Jimeno A, Sevilla I, Gravalos C. Phase I/II trial of capecitabine 
and gefi tinib in patients with advanced colorectal cancer after 
failure of fi rst-line therapy. Proc Am Soc Clin Oncol 2005; 23: 
3176a
38 Chau I, Massey A, Higgins L, Botwood N, Cunningham D. 
Phase I study of gefitinib in combination with irinotecan in 
patients with fl uoropyrimidine refractory advanced colorectal 
cancer (CRC). Proc Am Soc Clin Oncol 2004; 23: 263 (Abstract) 
39 Veronese ML, Sun W, Giantonio B, Berlin J, Shults J, Davis 
L, Haller DG, O'Dwyer PJ. A phase II trial of gefitinib with 
5-fluorouracil, leucovorin, and irinotecan in patients with 
colorectal cancer. Br J Cancer 2005; 92: 1846-1849
40 Hochhaus A, Hofheinz R, Heike M. Phase I study of gefi tinib 
in combination with FOLFIRI as 2nd-/3rd-line treatment in 
patients with metastatic colorectal cancer. Proc Am Soc Clin 
Oncol 2005; 23: 3674 (Abstract) 
41 Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, 
Fisher GA, Sikic BI. Phase II study of gefitinib, fluorouracil, 
leucovorin, and oxaliplatin therapy in previously treated 
patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 
5613-5619
42 Zeuli M, Gelibter A, Nardoni C. A feasibility study of gefi tinib 
in association with capecitabine (CAP) and oxaliplatin (OXA) 
as first-line treatment in patients with advanced colorectal 
cancer (ACRC). Proc Am Soc Clin Oncol 2004; 23: 306 (Abstract) 
43 Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan 
DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, 
Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KK, 
Morin MJ. Inhibition of epidermal growth factor receptor-
associated tyrosine phosphorylation in human carcinomas 
with CP-358,774: dynamics of receptor inhibition in situ and 
antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 
291: 739-748
44 Townsley CA, Major P, Siu LL, Dancey J, Chen E, Pond GR, 
Nicklee T, Ho J, Hedley D, Tsao M, Moore MJ, Oza AM. Phase 
II study of erlotinib (OSI-774) in patients with metastatic 
colorectal cancer. Br J Cancer 2006; 94: 1136-1143
45 Ouchi KF, Yanagisawa M, Sekiguchi F, Tanaka Y. Antitumor 
activity of erlotinib in combination with capecitabine in 
human tumor xenograft models. Cancer Chemother Pharmacol 
2006; 57: 693-702
46 Nakhoul I, Grossbard M, Blum R, Malamud S, Rodriguez T, 
Takhir M, Kozuch P. Phase II study of erlotinib in combination 
with capecitabine in previously untreated metastatic colorectal 
cancer. Proc Am Soc Clin Oncol GI Symp 2006: 239 (Abstract) 
47 Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, 
Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, 
5874        ISSN 1007-9327      CN 14-1219/R     World J Gastroenterol    November 28, 2007   Volume 13    Number 44
www.wjgnet.com
Fuchs CS. Phase II study of capecitabine, oxaliplatin, and 
erlotinib in previously treated patients with metastastic 
colorectal cancer. J Clin Oncol 2006; 24: 1892-1897
48 Nunes M , Shi C, Greenberger LM. Phosphorylation of 
extracellular signal-regulated kinase 1 and 2, protein kinase 
B, and signal transducer and activator of transcription 3 
are differently inhibited by an epidermal growth factor 
receptor inhibitor, EKB-569, in tumor cells and normal human 
keratinocytes. Mol Cancer Ther 2004; 3: 21-27
49 Casado E , Fo lprecht L , Paz-Ares L . A Phase I/ I IA 
pharmacokinetic and serial skin and tumor pharmacodynamic 
study of the EGFR irreversible tyrosine kinase inhibitor 
EKB-569 in combination with 5-fluorouracil leucovorin and 
irinotecan (FOLFIRI regimen) in patients with advanced 
colorectal cancer. Proc Am Soc Clin Oncol 2004; 23: 256 (Abstract) 
50 Tejpar S, Van Cutsem E, Gamelin E. Phase 1/2a study of 
EKB-569, an irreversible inhibitor of epidermal growth factor 
receptor, in combination with 5-fl uorouracil, leucovorin, and 
oxaliplatin (FOLFOX-4) in patients with advanced colorectal 
cancer (CRC). Proc Am Soc Clin Oncol 2004; 23: 265 (Abstract) 
51 Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, 
Novotny WF, Lieberman G, Griffi ng S, Bergsland E. Phase II, 
randomized trial comparing bevacizumab plus fluorouracil 
(FU)/leucovorin (LV) with FU/LV alone in patients with 
metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65
52 Hurwitz H , Fehrenbacher L, Novotny W, Cartwright 
T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, 
Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. 
Bevacizumab plus irinotecan, fl uorouracil, and leucovorin for 
metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
53 Kabbinavar F, Sulo A, Irl C, Nurwitz N. Bevacizumab 
improves outcomes of patients with metastasic colorectal 
cancer treated with IFL with or without bevacizumab 
independent of baseline risk. J Clin Oncol 2006; 24: 3539 
(Abstract)
54 Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell 
EP, Alberts SR, Schwartz MA, Benson AB 3rd. Bevacizumab 
in combination with oxaliplatin, fl uorouracil, and leucovorin 
(FOLFOX4) for previously treated metastatic colorectal cancer: 
results from the Eastern Cooperative Oncology Group Study 
E3200. J Clin Oncol 2007; 25: 1539-1544
55 Saltz L, Clarke S, diaz-Rubio E, Scheithauer W, Figer A, Wong 
R, Koski S, lichinister M, Yang T, Cassidy J. Bevacizumab 
in combination with XELOX or FOLFOX: Updated efficacy 
results from XELOX-1/N016966, a randomized phase III trial 
in fi rst line metastatic colorectal cancer. Proc Am Soc Clin Oncol 
2007; 170s: 4028 (Abstract) 
56 Kretzschmar A, Van Cutsem E, Michael M, rivera F, Berry 
S, DiBartolomeo M, Mazier M, Lutiger B, Cunningham D. 
Preliminary effi cacy of bevacizumab witj fi rst line FOLFOX, 
XELOX, FOLFIRI and monotherapy for m CRC: First 
BEATrial. Proc Am Soc Clin Oncol 2007; 181s: 4072 (Abstract) 
57 Reinacher-Schick A, Freier W, Dietrich G, Arnold D, Kanzler 
S, Geissier S, Graeven U, Hegewisch-Becker S, Schmoll H. 
Comparable safety and response rate with bevacizumab 
in combination with capecitabine/oxaliplatin versus 
capecitabine/irinotecan in advanced CRC: A randomized 
phase II study of the AIO GI tumor study group. Proc Am Soc 
Clin Oncol 2007; 172s: 4034 (Abstract) 
58 Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow 
L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS. Phase II 
multicenter trial of bevacizumab plus fluorouracil and 
leucovorin in patients with advanced refractory colorectal 
cancer: an NCI Treatment Referral Center Trial TRC-0301. J 
Clin Oncol 2006; 24: 3354-3360
59 Grothey A, Sugrue M, Hedrick E, Purdie D, Yi J, Dong W, 
Kozloff M. Association between exposure to bevacizumab 
beyond fi rst progression and overall survival in patients with 
metastatic colorectal cancer: Results fom a large observational 
study (BRiTE). Proc Am Soc Clin Oncol 2007; 172s: 4036 
(Abstract)
60 Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, 
Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, 
McMahon G. SU5416 is a potent and selective inhibitor of the 
vascular endothelial growth factor receptor (Flk-1/KDR) that 
inhibits tyrosine kinase catalysis, tumor vascularization, and 
growth of multiple tumor types. Cancer Res 1999; 59: 99-106
61 Rosen P, Amado R, Hecht J. A phase I/II study of SU5416 in 
combination with 5-FU/leucovorin in patients with metastatic 
colorectal cancer. Proc Am Soc Clin Oncol 2000; 18: 5a
62 Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, 
Gasparini G. Anti-angiogenic therapy: rationale, challenges 
and clinical studies. Angiogenesis 2002; 5: 237-256
63 Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, 
Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, 
Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-
Cook K, Menrad A, Siemeister G, Schirner M, Thierauch 
KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F. 
PTK787/ZK 222584, a novel and potent inhibitor of vascular 
endothelial growth factor receptor tyrosine kinases, impairs 
vascular endothelial growth factor-induced responses and 
tumor growth after oral administration. Cancer Res 2000; 60: 
2178-2189
64 Steward W, Thomas A, Morgan B. Expanded phase I/II study 
of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis 
inhibitor, in combination with FOLFOX-4 as first-line 
treatment for patients with metastatic colorectal cancer. Proc 
Am Soc Clin Oncol 2004; 23: 3556 (Abstract) 
65 Schleucher N, Trarbach T, Junker U, Tewes M, Masson 
E, Lebwohl D, Seeber S, Laurent D, Vanhoefer U. Phase 
I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral 
angiogenesis inhibitor in combination with FOLFIRI as fi rst-
line treatment for patients with metastatic colorectal cancer 
(CRC). Proc Am Soc Clin Oncol 2005; 23: 3605 (Abstract) 
66 Major P , Trarbach T, Lenz H, Kerr D, Pendergrass K, 
Douillard J, Chen B, Laurent D, Jacqes C, Van Cutsem E. A 
meta-analysis of two randomized, double-blind, placebo-
controlled, phase III studies in patients with metastatic 
colorectal cncer receiving FOLFOX and PTK/ZK to determine 
clinical benefit on progression free survival in high LDH 
patients. J Clin Oncol 2006; 18s: 3529 (Abstract) 
67 Lorusso PM, heath E, Valdivieso M, Pilat M, Wozniak A, 
Gadgeel S, Shields A, Puchalski R. Phase I evaluation of 
AZD2171, a highly potent and selective inhibitor of VEGFR 
signaling, in combination with selected chemotherapy 
regimens in patients with advanced solid tumors. J Clin Oncol 
2006; 24: 3034 (Abstract) 
68 Michael M, Tebbutt N, Gibbs P, Smith R, Godwood A, 
Oliver S. Vandetanib with FOLFOX6 in advanced colorectal 
adenocarcinoma: An open-label multicenter phase I study. 
Proc Am Soc Clin Oncol 2007; 187s: 4095 (Abstract).
69 Saunders M, Van Cutsem E, Wilson R, Peeters M, Smith R, 
Godwood A, Oliver S. Vandetanib with FOLFIRI in advanced 
colorectal adenocarcinoma: An open-label multicenter phase I 
study. Proc Am Soc Clin Oncol 2007: 184s: 4085 (Abstract) 
70 Jubb AM , Hurwitz HI, Bai W, Holmgren EB, Tobin P, 
Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, 
Frantz GD, Hillan KJ, Koeppen H. Impact of vascular 
endothelial growth factor-A expression, thrombospondin-2 
expression, and microvessel density on the treatment effect of 
bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006; 
24: 217-227
71 Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, 
Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan 
KJ, Koeppen H. Association of k-ras, b-raf, and p53 status with 
the treatment effect of bevacizumab. J Natl Cancer Inst 2005; 97: 
981-989
72 Shaye OS, Chang HM, Yang DY, Shriki J, Schutheis AM, 
Zhang W, Lurje G, Iqbal S, Lenz HJ. Polymorphisms in 
angiogenesis related genes predict clinical outcome in 
patients with metastatic colorectal cancer treated with first 
line 5-FU or caapecitabine in combination with oxaliplatin 
and bevacizumab. Proc Am Soc Clin Oncol 2007: 548s: 10576 
(Abstract) 
73 Tournigand C, lledo G, Delord J, Andre T, Maindrault-Goebel 
F, Louvet C, Scheithauer W, de Gramont A. Modifi ed Folfox/
Rodriguez J et al.  Targeted therapies-based combinations                                                                                  5875
www.wjgnet.com
bevacizumab or modifi ed Xelox/bevacizumab with or without 
erlotinib in fi rst line metastatic colorectal cancer. Results of the 
feasibility phase of the DREAM-OPTIMOX3 study (GERCOR). 
Proc Am Soc Clin Oncol 2007: 187s: 4097 (Abstract) 
74 Ocean AJ, Brien K, Lee J, Matthews N, Holloway S, Christos 
P, Kung TS, Kaubisch A, Chen H, Wadler S. Phase II trial 
of FOLFOX, bevacizumab and cetuximab in patients with 
colorectal cancer. Proc Am Soc Clin Oncol 2007: 182s: 4075 
(Abstract)
75 Schwartzberg LS, Hurwitz H, Stephenson J, Kotasek D, 
Goldstein D, Tebbutt N, Greivy J,Sun Y, Yang L, Burris H. 
Safety and pharmacokinetics of AMG 706 with panitumumab 
plus FOLFIRI or FOLFOX for the treatment of patients with 
metastatic colorectal cancer. Proc Am Soc Clin Oncol 2007: 183s: 
4081 (Abstract)
76 Kortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi 
S, Tong W, Sowers R, Gonen M, O'reilly E, Kemeny N, Ilson 
DI, Saltz LB, Maki RG, Kelsen DP, Schwartz GK. Phase I trial 
of the cyclin-dependent kinase inhibitor and protein kinase 
C inhibitor 7-hydroxystaurosporine in combination with 
Fluorouracil in patients with advanced solid tumors. J Clin 
Oncol 2005; 23: 1875-1884
77 Mita MM, Ochoa L, Rowinsky EK, Kuhn J, Schwartz G, 
Hammond LA, Patnaik A, Yeh IT, Izbicka E, Berg K, Tolcher 
AW. A phase I, pharmacokinetic and biologic correlative study of 
oblimersen sodium (Genasense, G3139) and irinotecan in patients 
with metastatic colorectal cancer. Ann Oncol 2006; 17: 313-321
78 Mackay H, Hedley D, Major P, Townsley C, Mackenzie 
M, Vincent M, Degendorfer P, Tsao MS, Nicklee T, Birle 
D, Wright J, Siu L, Moore M, Oza A. A phase II trial with 
pharmacodynamic endpoints of the proteasome inhibitor 
bortezomib in patients with metastatic colorectal cancer. Clin 
Cancer Res 2005; 11: 5526-5533
79 Lacombe DA, Caponigro F, Anthoney A, bauer J, Govaerts 
A, Milano A, Marreaud S, Twelves C. A phase I study of 
bortezomib in combination with FOLFOX4 in patients with 
advanced colorectal cancer: EORTC 16029. Proc Am Soc Clin 
Oncol 2007: 186s: 4090 (Abstract) 
80 Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors 
of cyclo-oxygenase 2: a new class of anticancer agents? Lancet 
Oncol 2003; 4: 605-615
81 Morabito A, Gattuso D, Sarmiento R. Rofecoxib associated 
with an antiangiogenic schedule of weekly irinotecan and 
infusional 5-fl uorouracil as second line treatment of patients 
with metastatic colorectal cancer: Results of a dose-finding 
study. Proc Am Soc Clin Oncol 2003; 22: 326 (Abstract)
82 Fuchs C, Marshall J, Mitchell E, Wieirzbicki R, Ganju V, 
Jeffery M, Schultz J, Richards DA, Soufi -Mahjoubi R, barrueco 
J. Updated results of BICC-C study comparing first line 
irinotecan/fluoropyrimidine combinations with or without 
celecoxib in CRC: Updated efficacy data. Proc Am Soc Clin 
Oncol 2007; 170s: 4027 (Abstract)
83 Struhl K. Histone acetylation and transcriptional regulatory 
mechanisms. Genes Dev 1998; 12: 599-606
84 Fakih MG , Pendyala L, Toth K, Creaven P, Soehnlein 
N, Litwin A, Trump D. A phase I Study of vorinostat in 
combination with FOLFOX in patients with advanced 
colorectal cancer. J Clin Oncol 2006; 24: 3592 (Abstract)
85 Klupp J, Langrehr JM, Junge G, Neuhaus P. Inhibitors of 
mammalian target of rapamycin. Drugs Fut 2001, 26: 1179-1188 
86 Skotnicki JS, Leone CL, Smith AL, Palmer Y, Yu K, Discafani 
CM, Gibbons JJ, Frost P, Abou-Gharbia MA. Design, synthesis 
and biological evaluation of C-42 hydrox-yesters of rapamycin: 
The identifi cation of CCI-779. AACR-NCI-EORTC Int Conf Mol 
Targets Cancer Ther 2001: 477 (Abstract)
87 Punt CJA, Bruntsch U, Hanauske AR, Weigang-Köhler, K., 
Peters M, Thielert C, Frisch J. A phase I study of escalating 
doses of CCI-779 in combination with 5-fluorouracil and 
leucovorin in patients with advanced solid tumors. Eur J 
Cancer 2001; 37: 53 (Abstract)
S- Editor  Liu Y    L- Editor  Alpini GD    E- Editor  Wang HF 
5876        ISSN 1007-9327      CN 14-1219/R     World J Gastroenterol    November 28, 2007   Volume 13    Number 44
www.wjgnet.com
